Results 51 to 60 of about 123,475 (261)

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree, Beatrice Suero, Sarah Walsh, Romain Marignier, John W. Lindsey, Ho Jin Kim, Dewei She, Daniel Cimbora, Dustin Cavida, Friedemann Paul   +9 more
wiley   +1 more source

Impact of high cholesterol and endoplasmic reticulum stress on metabolic diseases: An updated mini-review

Redox Biology, 2017
Endoplasmic reticulum (ER) is the major site of protein folding and calcium storage. Beside the role of ER in protein homeostasis, it controls the cholesterol production and lipid-membrane biosynthesis as well as surviving and cell death signaling ...
Erdi Sozen, Nesrin Kartal Ozer
doaj   +1 more source

Role and Mechanisms of Mitophagy in Liver Diseases

Cells, 2020
The mitochondrion is an organelle that plays a vital role in the regulation of hepatic cellular redox, lipid metabolism, and cell death. Mitochondrial dysfunction is associated with both acute and chronic liver diseases with emerging evidence indicating ...
Xiaowen Ma, Tara McKeen, Jianhua Zhang, Wen-Xing Ding   +3 more
doaj   +1 more source

Propylthiouracil for alcoholic liver disease [PDF]

Cochrane Database of Systematic Reviews, 2011
Randomised clinical trials have addressed the question whether propylthiouracil has any beneficial effects in patients with alcoholic liver disease.To assess the beneficial and harmful effects of propylthiouracil for patients with alcoholic liver disease.We searched The Cochrane Hepato-Biliary Group Controlled Trials Register (April 2011), The Cochrane
Giuseppe, Fede, Giacomo, Germani, Christian, Gluud, Kurinchi Selvan, Gurusamy, Andrew K, Burroughs   +4 more
openaire   +2 more sources

Evaluation of Digital Technologies for Home‐Based Assessment in People With Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Digital technologies hold promise for transforming healthcare by enhancing personalized treatments and offer valuable opportunities to improve patient care. Here, we evaluated several novel, self‐administered, home‐based, digital endpoints for their association with corresponding conventional standard clinical measures (primary) in ...
Arne Mueller, Vanessa Vallejo, Mónica Povedano Panadés, Orla Hardiman, Véronique Danel‐Brunaud, Senda Ajroud‐Driss, Philippe Couratier, Jeremy Shefner, Anna Gokey, Mike DiCesare, Erin Lennox, Jens Praestgaard, Lucie Brujin, Peggy Allred, Ram Miller   +14 more
wiley   +1 more source

Features of therapeutic options for the treatment of non-alcoholic fatty liver disease and carbohydrate metabolism disorders

Лечащий Врач
Background. Diabetes mellitus is one of the most common diseases worldwide, and non-alcoholic fatty liver disease is recognized as the most common chronic liver disease worldwide.
N. A. Petunina, M. E. Telnova, E. V. Goncharova, I. A. Kuzina   +3 more
doaj   +1 more source

Factors Associated With the Rising Trend in Self‐Reported Cognitive Disability Among U.S. Adults Aged 18–39 From 2013–2024

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Building on our prior Behavioral Risk Factor Surveillance System analysis identifying adults aged 18–39 as the primary driver of the national increase in self‐reported cognitive disability, we examined factors associated with this rise using 2013–2024 U.S. BRFSS data. Methods We analyzed U.S.
Adam de Havenon, Ka‐Ho Wong, Mirriam Mananah, Christopher D. Anderson, Ada Fenick, Amy Arnsten, Arman Fesharaki‐Zadeh, James C. McPartland, Mary L. Adams, Kevin N. Sheth   +9 more
wiley   +1 more source

Metabolically associated fatty liver disease. What is the danger of a "safe" disease? Pathogenesis of cardiovascular complications

Лечащий Врач
Background. Nonalcoholic fatty liver disease is most often a latent disease with absent or mild clinical manifestations. It is usually detected as an incidental finding when transaminase levels are elevated or imaging signs of fatty liver degeneration ...
M. A. Isaikina, O. Yu. Isaykina, O. Yu. Trushina   +2 more
doaj   +1 more source

Obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study

BMC Gastroenterology, 2021
Background Hepatic steatosis has a pivotal role in the development of chronic liver diseases, even in alcohol-related liver disease. Alcoholic fatty liver disease is an important phenotype among alcohol-related liver diseases. While metabolic syndrome is
Yuta Yoshimura, Masahide Hamaguchi, Yoshitaka Hashimoto, Takuro Okamura, Naoko Nakanishi, Akihiro Obora, Takao Kojima, Michiaki Fukui   +7 more
doaj   +1 more source

Liver regeneration and alcoholic liver disease

Annals of Translational Medicine, 2020
Alcoholic liver diseases (ALD) are a wide spectrum of liver diseases caused by excessive alcohol consumption, from steatosis to cirrhosis. The pathogenesis of ALD is insufficiently understood, but mainly involves oxidative stress, inflammation, bacterial translocation, cell death, and impaired regeneration.
Lv, Yi, So, Kwok Fai, Xiao, Jia
openaire   +2 more sources